Expectedly, 25–64% of the mAbs from each donor had measurable receptor-blocking activity (IC50 < 5 μg/ml), suggesting that most of the RBD-specific NAbs protect against virus infection via mechanisms that block attachment to the cellular receptor ACE2 (Fig. 1c). Here, ACE2 is linked to viral infectious disease.